Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053307 | 0.78 | GAA (0.40) | ALDH1A1HPGDKDM4EL3MBTL1SRC | |
| SCHEMBL16631789 | 0.77 | CYP2C9 (0.40) | KDM4EGAAHSD17B10 | |
| SCHEMBL11213165 | 0.73 | MAPK8 (0.39) | MAPK8MAPK9PDE4BPDE4CPDE4D | |
| SCHEMBL30488636 | 0.72 | SLC22A12 (0.33) | — | |
| SCHEMBL21222821 | 0.72 | SLC22A12 (0.33) | — | |
| SCHEMBL3082319 | 0.71 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EHTTL3MBTL1 | |
| SCHEMBL6624693 | 0.71 | KDM4E (0.45) | MAPK8ALDH1A1KDM4EMEN1TSHR | |
| SCHEMBL13362524 | 0.70 | ALDH1A1 (0.49) | ALDH1A1HPGDAR | |
| SCHEMBL6624700 | 0.70 | CNR2 (0.37) | MAPK8MAPK9ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6625524 | 0.70 | MEN1 (0.44) | MAPK8MAPK9ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794387-B2 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (CGMP PDE5) INHIBITORS; 2-(5-ACETYL-2-BUTOXY-3-PYRIDINYL)-7-ETHYL-5-METHYLIMIDAZO(5,1 -F)(1,2,4)TRIAZIN-4(3H)-ONE FOR EXAMPLE | PFIZER INC. | 2004-09-21 | — | — | US | disclosed |
| EP-1395589-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS | Pfizer Limited (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1380293-A1 | BONE METABOLISM IMPROVING AGENTS | The Nisshin OilliO, Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1092719-B1 | Imidazo[5,1-f][1,2,4]triazine derivatives | PFIZER LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-6503908-B1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors; sexual disorders | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| US-20020177599-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002079203-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| EP-1092719-A2 | Imidazo[5,1-f][1,2,4]triazine derivatives | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177599-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | MAPK8 3217/4885MAPK9 2524/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.